Clinicians are likely to encounter delirium frequently, particularly in inpatient and intensive care settings. However, delirium is underrecognized and undertreated because of its heterogeneous and fluctuating presentation and due to the limitations in resources and training in contemporary clinical settings. Translation of current knowledge about delirium into clinical practice may improve patient care and benefit public health economics. Hence, this review comprehensively discusses the phenomenology and pathophysiology of delirium and its presenting features, risk factors, differential diagnoses, assessment, prognosis, and treatment with antipsychotics; the goal is to facilitate better prevention, recognition, and treatment of delirium. Available research is reviewed, limitations of the research are discussed, and future directions for further delirium research are identified.
Bibliographical noteFunding Information:
Dr. Pae has received research support/honoraria from Glaxo-SmithKline Korea, GlaxoSmithKline, AstraZeneca Korea, Janssen Pharmaceutica Korea, Eli Lilly and Co Korea, the Korean Research Foundation, Otsuka Korea, Wyeth Korea, McNeil Consumer and Specialty, and the Korean Institute of Science and Technology Evaluation and Planning and serves on the speakers’ bureau for Glax-oSmithKline Korea, Lundbeck Korea, AstraZeneca Korea, Janssen Pharmaceutica Korea, Eli Lilly and Co Korea, and Otsuka Korea.
Dr. Han has received research support from Korea Research Foundation grant MOEHRD (KRF-2007-013-E00033) and from a Korea University Neuropsychiatric alumni grant.
Dr. Patkar serves as a consultant for Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; serves on the speakers’ bureau for Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; and has received research support from the National
ASJC Scopus subject areas
- Psychiatry and Mental health